TrialThe oncologist2020

Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601).

Atsushi Nakamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.